Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Lapatinib; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TEAL
- 07 Jun 2017 Biomarkers information updated
- 07 Oct 2015 Added pertuzumab to drug descriptors and modified the treatment table, title and purpose to reflect the protocol changes reported by the ClinicalTrials.gov.
- 07 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrial.gov.